Abbott has completed its acquisition of Exact Sciences, making the cancer diagnostics company a wholly owned subsidiary and strengthening Abbott’s position in the rapidly growing cancer screening and precision diagnostics market. Following the transaction, Exact Sciences has been delisted from Nasdaq, marking its full integration into Abbott’s operations.
The acquisition significantly expands Abbott’s capabilities in early cancer detection and personalized treatment, aligning with its strategy to focus on more preventive, predictive, and patient-specific care. The deal introduces a new growth engine for Abbott, supporting its expectation of sustained high-single-digit growth.
Through the integration, Abbott gains access to a robust portfolio of cancer diagnostics, including Cologuard for noninvasive colorectal cancer screening, Oncotype DX for guiding treatment decisions in early-stage breast cancer, Oncodetect for monitoring molecular residual disease and recurrence, and Cancerguard, a multi-cancer early detection blood test. The pipeline also includes next-generation tools designed to detect cancer earlier, optimize treatment pathways, and enable ongoing disease monitoring.
Abbott leadership emphasized that combining its global scale and commercial reach with Exact Sciences’ expertise will help expand access to advanced cancer diagnostics worldwide and accelerate innovation in precision oncology.
Click here to read the original news story.
